Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Kimberly Aung"'
Autor:
Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C. Armstrong, Richard Baird, Erika Hamilton, Seock‐Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 1969-1985 (2022)
Nearly all estrogen receptor (ER)‐positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events
Externí odkaz:
https://doaj.org/article/3982ed92674c47fd83894acff6f5a9d3
Autor:
Costanza Paoletti, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga, Minetta C. Liu, P. Kelly Marcom, Lowell L. Hart, John W. Smith, Karen L. Tedesco, Eitan Amir, Ian E. Krop, Angela M. DeMichele, Pamela J. Goodwin, Margaret Block, Kimberly Aung, Martha E. Brown, Robert T. McCormack, Daniel F. Hayes
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, mi
Externí odkaz:
https://doaj.org/article/a4591a6d3a9d4069a97a9133183bb04c
Autor:
Costanza Paoletti, Jose M. Larios, Maria C. Muñiz, Kimberly Aung, Emily M. Cannell, Elizabeth P. Darga, Kelley M. Kidwell, Dafydd G. Thomas, Nahomi Tokudome, Martha E. Brown, Mark C. Connelly, David A. Chianese, Anne F. Schott, N. Lynn Henry, James M. Rae, Daniel F. Hayes
Publikováno v:
Molecular Oncology, Vol 10, Iss 7, Pp 1078-1085 (2016)
Fulvestrant is a dose dependent selective estrogen receptor (ER) down‐regulator (SERD) used in ER‐positive metastatic breast cancer (MBC). Nearly all patients develop resistance. We performed molecular analysis of circulating tumor cells (CTC) to
Externí odkaz:
https://doaj.org/article/7957be4d2fea493c9246bb9e97afb0c8
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Background: Endocrine therapy (ET) fails to induce a response in one half of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC), and almost all will eventually become refractory to ET. Circulating tumor cells (CTC) are asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aadf3ff396caa8046785d07ed87e779
https://doi.org/10.1158/1078-0432.c.6524091.v1
https://doi.org/10.1158/1078-0432.c.6524091.v1
Autor:
Daniel F. Hayes, Richard Baird, J. Carl Barrett, Elizabeth A. Harrington, Caroline Dive, Fouziah Butt, Nadia Iqbal, Seock-Ah Im, Komal Jhaveri, Anne Armstrong, Manish Patel, Erika Hamilton, Kimberly Aung, Nitharsan Sathiyayogan, Vicky Rowlands, Parul Patel, Shethah Morgan, Gayle Marshall, Justin Lindemann, Teresa Klinowska, Matthias Hoch, Joseph Geradts, T. Hedley Carr, Elizabeth P. Darga, Emily M. Dolce, Gaia Schiavon, Costanza Paoletti
Supplementary Figures: Supplementary Figure 1. Summary of duration on AZD9496 therapy, previous therapies, and circulating biomarkers status at baseline for each patient ranked by ascending dose; Supplementary Figure 2. Tumor pharmacodynamics. Supple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a52dc9d60aefb975153d05abcb1fe32
https://doi.org/10.1158/1078-0432.22469739.v1
https://doi.org/10.1158/1078-0432.22469739.v1
Autor:
Scott A. Tomlins, James M. Rae, Daniel F. Hayes, Ben H. Park, Michael D. Johnson, Farideh Z. Bischoff, Arul M. Chinnaiyan, Dan R. Robinson, Robert Lonigro, Yi-Mi Wu, Anne F. Schott, Christina Gersch, Dafydd G. Thomas, Nahomi Tokudome, Valeria Sero, Allen R. Blevins, Maryam Yazdani, David Chu, Chia-Jen Liu, Paul J. Baratta, Emily M. Cannell, Elizabeth P. Darga, Kimberly Aung, Daniel H. Hovelson, Jose M. Larios, Andi K. Cani, Costanza Paoletti
Addressing drug resistance is a core challenge in cancer research, but the degree of heterogeneity in resistance mechanisms in cancer is unclear. In this study, we conducted next-generation sequencing (NGS) of circulating tumor cells (CTC) from patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a18b5cd5f96f693020b929a06018a2
https://doi.org/10.1158/0008-5472.c.6510609.v1
https://doi.org/10.1158/0008-5472.c.6510609.v1
Autor:
Daniel F. Hayes, Richard Baird, J. Carl Barrett, Elizabeth A. Harrington, Caroline Dive, Fouziah Butt, Nadia Iqbal, Seock-Ah Im, Komal Jhaveri, Anne Armstrong, Manish Patel, Erika Hamilton, Kimberly Aung, Nitharsan Sathiyayogan, Vicky Rowlands, Parul Patel, Shethah Morgan, Gayle Marshall, Justin Lindemann, Teresa Klinowska, Matthias Hoch, Joseph Geradts, T. Hedley Carr, Elizabeth P. Darga, Emily M. Dolce, Gaia Schiavon, Costanza Paoletti
Purpose:Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)–positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm). ESR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d19b6ff53bf7d9bdb2da2810051c15
https://doi.org/10.1158/1078-0432.c.6527325.v1
https://doi.org/10.1158/1078-0432.c.6527325.v1
Autor:
Daniel F. Hayes, David A. Chianese, Mark C. Connelly, James M. Rae, N. Lynn Henry, Anne F. Schott, Dorothy L. Blossom, M. Craig Miller, Kimberly Aung, Martha E. Brown, Nahomi Tokudome, Kelley M. Kidwell, Kent A. Griffith, Dafydd G. Thomas, Maria C. Muñiz, Costanza Paoletti
Table S1. Antibodies used for CTC and tissue studies. Table S2. Stage 2 stopping rules for the cumulative number of successfully assayed patients. Table S3. A. CTC-Enumeration Points based on CTC Enumeration B. CTC-Bio-Pointsa Footnotes:aOnly aliquot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0a31083669e29babf1577e42bdba37
https://doi.org/10.1158/1078-0432.22458948
https://doi.org/10.1158/1078-0432.22458948
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Purpose: Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). We tested whether EpCAM-based capture system (CellSearch) is effective in patients with triple-negative (TN) MBC, and whether CTC apoptosis and clustering enhanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc82a93b4e8341969db7d17885cb8b88
https://doi.org/10.1158/1078-0432.c.6524666
https://doi.org/10.1158/1078-0432.c.6524666
Autor:
Daniel F. Hayes, Andres Forero-Torres, Antonio C. Wolff, Catherine H. Van Poznak, Christos Vaklavas, Tiffany A. Traina, Anna M. Storniolo, Julie R. Nangia, Rita Nanda, Minetta C. Liu, Nancy U. Lin, William J. Irvin, Vandana G. Abramson, Martha E. Brown, Dafydd G. Thomas, Kimberly Aung, Kelley M. Kidwell, Maria C. Muñiz, Yufeng Li, Costanza Paoletti
Supplementary Figure 1-5. Supplementary Figure 1. Example of cluster image using the CellSearch® system. Supplementary Figure 2. REMARK diagram of the 19 patients who had elevated CTC (Group B/C) at baseline that were used to study "CTC-response". S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97e12e73b7c8b510c104658757ec14d6
https://doi.org/10.1158/1078-0432.22460996
https://doi.org/10.1158/1078-0432.22460996